Megasolone

Prednisolone Acetate

Method of action: Antiallergic, Anti-Inflammatory, Corticosteroids For Systemic Use, Endocrine-Metabolic Agent, Immunosuppressive, Ophthalmologicals

Treatment option: Agranulocytosis, Addison's Disease, Allergy, Anaphylaxis, Anemia, Ankylosing Spondylitis, Arthritis,Osteoarthritis, Aspergillosis,Aspergilloma, Asthma, Asthma With Status Asthmaticus

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Megasolone

Property	Description
Active ingredient	Prednisolone Acetate
Form	Suspension, Solution, Tablets, Syrups, Topical preparations
Pharmacological class	Glucocorticoid (Adrenocortical Steroid)
General purpose	Anti-inflammatory and Immunosuppressive action
Origin	Synthetic; Ester derivative

What is the Active Ingredient and Class of Megasolone?

Megasolone is a pharmaceutical preparation defined by its active component, Prednisolone Acetate, which belongs to the powerful category of synthetic adrenocortical steroids. This compound is specifically classified as a glucocorticoid, a class of medications designed to mimic the action of hormones naturally produced by the adrenal glands.

The drug is a man-made ester form of the base compound, Prednisolone, making it a highly potent single-ingredient product. The acetate modification, which differentiates it from its base form, is clinically recognized for influencing the solubility and duration of effect, often rendering it suitable for various pharmaceutical preparations where sustained local or systemic action is required. The presence of this ester form allows the medicine to sustain its action over time.

What is the General Purpose of Prednisolone Acetate Therapy?

The fundamental purpose of Megasolone therapy is to act as a potent anti-inflammatory agent and immunosuppressant to manage conditions characterized by excessive immune activity. This drug's classification allows it to broadly modulate the body's internal defense systems, rather than targeting a single specific symptom.

This broad action is utilized to provide relief by suppressing the intense symptoms associated with severe systemic inflammation, pronounced allergic reactions, and the inappropriate activity seen in various autoimmune diseases. The therapeutic aim is to restore stability by significantly reducing the underlying inflammatory and immune responses that cause patient discomfort or tissue damage.

In What Forms is Megasolone Available?

Megasolone, or Prednisolone Acetate, is produced in diverse dosage forms tailored for specific therapeutic routes, ensuring either localized or body-wide effect. These forms include a sterile preparation often presented as a suspension for injectable use, clear solutions such as ophthalmic drops, and solid oral forms like tablets. The injectable suspension is a differentiating feature, often chosen when a long-acting local effect is desired, such as for intra-articular administration.

The availability of both systemic forms (like tablets) and local preparations (like topical creams or eye drops) ensures that the powerful anti-inflammatory effects of this glucocorticoid can be accurately targeted. The selection of the form dictates whether the medicine provides concentrated treatment for a specific area, such as local inflammation, or exerts a general effect throughout the body.

Regulatory References

glucocorticoid

What side effects are possible with Megasolone?

Possible Side Effects and Safety Information

The safety profile of Prednisolone Acetate (Megasolone), a systemic glucocorticoid, is defined by adverse reactions categorized by System Organ Class (SOC) and frequency, as documented in regulatory labeling. The medicine's actions can affect multiple physiological systems, reflecting a broad, systemic risk context.

Official Adverse Reaction Categories

Adverse effects listed as Common in regulatory documents often involve Metabolism and Nutrition Disorders (e.g., fluid retention, weight gain, alteration in glucose tolerance) and Psychiatric Disorders (e.g., mood swings, insomnia). Less common, but documented, effects can impact Ophthalmic Disorders (e.g., cataracts, glaucoma) and the Gastrointestinal system (e.g., peptic ulceration).

Serious Adverse Reactions and Safety Patterns

The regulatory safety notes highlight specific serious adverse reactions. These include a heightened risk of infection due to the immunosuppressive effect, and the potential for acute adrenal insufficiency upon cessation after chronic use. The risks of osteoporosis and cataract formation are primarily associated with prolonged systemic exposure.

Population-Specific Safety

Official labeling includes safety considerations for specific groups. In the pediatric population, systemic use is associated with the risk of growth retardation. Older adults may be at increased risk for adverse effects such as osteoporosis and hypertension. Furthermore, safety statements exist regarding potential fetal harm during early pregnancy and effects on nursing infants.

Overdose and Emergency Response

Megasolone Overdose and when to seek help

The official regulatory documentation for Megasolone (Prednisolone Acetate) indicates that acute overdosage is generally not expected to produce life-threatening symptoms, and specific treatment may be unlikely to be needed. However, the regulatory focus addresses the severe consequences resulting from prolonged exposure to high doses (chronic toxicity).

Documented Manifestations and Severe Outcomes

Overdose resulting from long-term high-dose use is officially documented to manifest as severe physiological changes, including the development of a Cushingoid state, hypertension, and fluid retention. Other documented manifestations include psychic derangements such as euphoria or psychosis, as well as severe fluid and electrolyte imbalance (hypokalemic alkalosis).

Regulator-listed severe outcomes requiring urgent attention are convulsions, the onset or worsening of congestive heart failure in susceptible patients, and major gastrointestinal complications such as peptic ulcer with possible perforation and hemorrhage.

Required Emergency Actions

Immediate medical attention must be sought for any severe or life-threatening symptoms, as these outcomes demand urgent clinical management. Regulatory documents confirm that no specific antidote is known for Prednisolone Acetate overdose. Therefore, management is defined as symptomatic and supportive treatment with continuous clinical monitoring, particularly for electrolyte status. Additionally, official labeling states that infants born to mothers who received substantial doses must be observed for hypoadrenalism.

Therapeutic Uses of Megasolone

What Megasolone Treats: Main Uses and Benefits

Megasolone is applied in clinical settings that involve acute or unstable symptom patterns, such as crisis states involving pronounced systemic inflammation or during flare-ups of chronic conditions like certain rheumatic and gastrointestinal disorders. The medication is commonly used across conditions presenting with acute episodes, including the management of pronounced symptoms linked to severe allergic reactions and the disruptive symptom manifestations of autoimmune disorders. This helps provide support that assists in easing the overall symptom burden.

The medication is also relevant in contexts involving heightened systemic burden, and may be applied in managing symptoms related to localized inflammatory processes, such as in ophthalmic conditions like uveitis and iritis, and certain dermatologic diseases. It assists with managing symptom clusters that may become intense or disruptive, offering symptomatic relief that helps improve day-to-day comfort during symptomatic periods. The medication supports the patient during difficult episodes by easing discomfort.

“It is commonly used to help with symptoms that create noticeable physiological strain and may interfere with daily functioning.”

Quick Fact: Symptomatic Support for Inflammatory States

Regulatory References

FDA DailyMed overview for PredniSONE

Eligibility and Restrictions for Use

Who Can and Cannot Use Megasolone?

Megasolone eligibility is strictly defined by regulatory documents, categorizing populations into those with absolute prohibitions and those requiring conditional use based on the patient's specific physiological status.

Eligibility Scope

Classification	Official Regulatory Status
Populations for whom use is contraindicated	Patients with known Systemic Fungal Infections, documented Hypersensitivity to the drug, or those requiring Live Virus Immunization while receiving immunosuppressive doses. For ophthalmic forms, specific ocular viral infections (e.g., Herpes Simplex Keratitis) are prohibited.
Age-related eligibility rules	Children on long-term therapy must be monitored for potential effects on growth. Older adults require caution due to the likelihood of age-related renal or hepatic issues.
Condition-specific eligibility rules (Use with Caution)	Caution is explicitly required in individuals with Renal Insufficiency, Hepatic Failure/Cirrhosis, Diabetes Mellitus, Active Peptic Ulceration, or Latent Tuberculosis.
Pregnancy and lactation eligibility status	Pregnancy use requires a formal benefit-risk assessment due to the labeled risk of fetal harm. Lactating mothers must consider discontinuing nursing or the medication.

Connection to the Overall Eligibility Profile

This profile establishes absolute non-eligibility based on immune status and hypersensitivity. Use in most other populations is conditional, contingent upon careful risk assessment and monitoring of underlying disease states, organ function, and pediatric development, as mandated by official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information outlines several categories of drugs that interact with Megasolone, necessitating monitoring or dosage adjustments.

Interacting Product Category	Official Interaction Constraint/Requirement
Antidiabetic Agents	May increase blood glucose concentrations. Dosage adjustments of antidiabetic agents (e.g., insulin or oral agents) may be required.
CYP 3A4 Inducers (e.g., Rifampin)	May increase the clearance of Megasolone, potentially decreasing its effect. A dosage increase for Megasolone may be required.
CYP 3A4 Inhibitors (e.g., Ketoconazole)	May decrease the clearance of Megasolone, potentially increasing its effect. A dosage decrease for Megasolone may be required.
Anticoagulants (Oral)	Coagulation indices (e.g., INR) must be monitored frequently to maintain the desired anticoagulant effect, as co-administration can alter the response to these medicines.
Cyclosporine	Concurrent use may result in increased activity of both medications. Convulsions have been reported with this co-administration.
NSAIDs and Salicylates	Increased risk of gastrointestinal side effects.

Specific medicines like Indinavir are officially noted to have their exposure significantly decreased when co-administered, requiring consideration of a higher Indinavir dose. For patients with diabetes mellitus, the glucose-elevating effect of Megasolone is a particular interaction-context constraint that guides co-administration management.

Mechanism of Action

How Megasolone Works: Modulation of Gene Expression and Immune Signaling

Megasolone works primarily by acting as an agonist at the Glucocorticoid Receptor (GR), a protein found inside cells. The activated drug-receptor complex enters the cell nucleus and modulates gene transcription to regulate the synthesis of specific proteins. This foundational action is responsible for two major physiological consequences: the significant suppression of inflammatory signaling and the dampening of the body's immune responses.

Dampening Inflammatory Signals

This mechanistic domain centers on the inhibition of key pro-inflammatory molecular cascades. The drug-receptor complex suppresses the action of transcription factors like NF-kappaB, which are necessary to produce inflammatory mediators such as cytokines and chemokines. It also interferes with the enzyme Phospholipase A2 ( PLA2), which reduces the creation of substances that promote inflammation. This mechanism leads directly to a significant reduction in physiological signs associated with the inflammatory process, including reduced vasodilation and decreased tissue fluid accumulation.

Altering Cellular Immune Function

This domain describes how Megasolone changes the activity and distribution of the body's white blood cells. The drug's influence causes immune cells, like lymphocytes, to be temporarily redistributed away from the bloodstream and into lymphatic tissues. By changing the number and location of these cells, as well as impairing their responsiveness, this mechanism reduces the cellular activity of the immune system.

Dosage and Administration Information

Megasolone (Prednisolone Acetate) is administered via specific, approved routes depending on the preparation. The medicine is available as an oral suspension for systemic use and an ophthalmic suspension administered by topical ocular instillation. The ophthalmic preparation is strictly restricted for ocular use and is not intended for injection or ingestion.

The systemic initial adult dosage may vary, ranging from 5 mg to 60 mg per day (prednisolone base equivalent), and the final dose must be individualized according to the disease and patient response. The oral suspension should be consumed with food to adhere to administration requirements.

The frequency of application for the ophthalmic suspension is typically defined as two to four times daily. However, during the initial 24 to 48 hours of an acute inflammatory episode, the frequency may be increased to up to two drops every hour. Both the oral and ophthalmic preparations are formulated as suspensions and must be shaken well before use.

Regarding high-level administration rules, no overall adjustment to the adult ophthalmic dosage is recommended for older adults. The medicine is intended for short-term treatment, and for long-term systemic use, therapy must not be discontinued prematurely. Withdrawal from extended courses of the systemic preparation must be performed gradually (tapering) to manage the patient's physiological transition from the medication.

Recent Clinical Evidence

Megasolone: Overview of Studies

Research Evidence for Ocular Inflammation (Topical Use)

Clinical evaluation was conducted for conditions involving an irritative or inflammatory state in the eye, such as post-surgical inflammation following cataract procedures and the heightened symptom activity associated with anterior uveitis. This research has primarily utilized Randomized Controlled Trials (RCTs).

Researchers monitored specific physiological measures, including anterior chamber cell count and flare, which are measures monitored in studies. In trials assessing inflammation, studies reported measurements of change in these markers in comparison to control or placebo. Some trials described patterns in patient-reported outcomes for physical discomfort (pain) that were comparable to those observed with other steroid eye drops.

Research Evidence for Systemic Inflammatory and Autoimmune Conditions

Megasolone is a glucocorticoid, and its systemic use is interpreted by the established research base for this entire class of medications. This evidence structure includes Systematic Reviews and Meta-analyses that have explored how symptoms change over time in patients with various conditions.

Research examined the use of glucocorticoids in patients with conditions presenting with cycles of stability and flare-ups, such as certain autoimmune diseases. Studies reported how symptoms evolved in the observed populations, and findings indicate that this class is often studied alongside other agents in research exploring the underlying systemic processes.

What is Still Uncertain About Megasolone Research

Research contributes to the broader evidence landscape, but several limitations are documented. Long-term effects are not fully established for the maintenance of reduced inflammation or for sustained systemic stability in all conditions studied. For the systemic indications, the vast majority of findings describe the effects of the entire glucocorticoid class, and data for the specific acetate form remain insufficient to define its unique contribution apart from the parent compound. Furthermore, sample sizes were modest in some of the pivotal ocular inflammation studies.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Megasolone (FAQ)

Q: Do all conditions treated by Megasolone involve inflammation?

Megasolone is officially classified as a potent anti-inflammatory and immunosuppressive medication. Its fundamental purpose is described as anti-inflammatory and to suppress excessive immune activity. Therefore, its approved indications cover a broad range of conditions that are characterized by these underlying systemic processes.

Q: Are the body shape changes described by users, such as 'moon face,' officially listed as side effects?

Official regulatory documentation describes side effects that involve changes in metabolism and fat deposits. Specifically, it lists 'Cushingoid state' and the development of 'abnormal fat deposits' on the face, neck, and trunk. These descriptions align with the appearance commonly referred to as 'moon face.'

Q: How long is Megasolone considered a short-term treatment versus a prolonged course of treatment?

Official guidelines often refer to short-term use as lasting for less than three or four weeks. Use that extends beyond this duration is typically classified as prolonged or long-term. Prolonged exposure is associated with an increased risk of certain adverse effects and requires a gradual dose reduction when stopping the medication.

Q: What does 'adrenal suppression' or 'HPA axis suppression' mean in relation to Megasolone?

Adrenal suppression is a potential effect where the body's natural hormone production is reduced. Because the synthetic steroid mimics and replaces natural hormones, it causes the adrenal and pituitary glands to suppress the body's own output of cortisol. This effect is why official guidance recommends the medicine be tapered gradually after extended use to allow the body to resume normal function.

Q: Are there official recommendations for regular monitoring (e.g., blood sugar) during long-term Megasolone use?

Official guidelines indicate that certain parameters are often monitored during long-term therapy. Due to the risk of bone loss, bone density screening and supplementation with calcium and Vitamin D may be recommended. Monitoring for changes in blood glucose levels may also be necessary, especially for individuals with pre-existing diabetes.

Q: Are there large-scale studies that have examined the long-term impact of Megasolone?

The research base for Megasolone's systemic use relies on the established evidence for the entire glucocorticoid class, including Systematic Reviews and Meta-analyses. However, the official evidence states that specific long-term data for the Prednisolone Acetate form are often cited as limited.

Q: What is the typical duration of the effects of a single dose of Megasolone?

Official pharmacology information indicates that the acetate form of the medicine is chemically structured to influence its solubility. This formulation is intended to provide a sustained action over time, but the specific duration of effect following a single systemic dose is not quantified in the label.

Q: Is an increased appetite a common expectation when taking Megasolone?

Yes, according to official safety information, increased appetite is listed as a commonly reported effect under the category of metabolism and nutrition disorders.

Q: Does Megasolone commonly cause easy bruising or thinning of the skin?

Official safety information lists dermatologic side effects that include thin fragile skin and ecchymoses (the medical term for bruising). These effects are documented as possible adverse reactions associated with the use of this medication.

Q: What is the purpose of a steroid emergency card, and who is advised to carry one?

The steroid emergency card is a notification tool made available to patients receiving specific prolonged doses of the drug or those with adrenal insufficiency. Its purpose is to inform emergency health professionals that the patient may need an immediate, higher dose of steroids during severe stress or illness. This is a measure intended to help manage a rare, but serious, complication known as adrenal crisis.

Q: Is there an official statement on whether Megasolone interacts with alcohol consumption?

Official regulatory documents do not list a specific direct interaction between Megasolone and alcohol consumption in the product labeling. However, the medicine is officially noted to increase the risk of gastrointestinal side effects, such as peptic ulceration. The general risk of gastrointestinal side effects may be elevated when co-administered with irritants.

Q: Why are people sometimes advised to take Megasolone first thing in the morning?

Official guidance suggests that taking the medicine as a single dose in the morning is a common recommendation to align with the body’s natural rhythm of cortisol production. This timing is associated with an approach to help manage adrenal gland suppression and common side effects like insomnia.

Q: Does official information address whether Megasolone can cause or worsen acne?

Yes, official safety information lists acne as a possible dermatologic adverse reaction. This is documented alongside other skin-related effects associated with the use of the drug.

Q: Are the side effects on appearance and weight gain described as reversible once the medicine is stopped?

Information from government health authorities suggests that side effects related to appetite, water retention, and changes in body shape generally subside or return to normal over time. This process typically occurs once the medicine is stopped or the dose is significantly reduced following a medical plan.

Q: Is Megasolone known to affect wound healing time?

Yes, official safety information lists impaired wound healing as a possible side effect. This is described as slowed healing of cuts and bruises under the official dermatologic adverse reactions category.

Q: How quickly does Megasolone begin to reduce inflammation after starting treatment?

Official pharmacology information describes the medicine as readily absorbed from the gastrointestinal tract following oral administration. The anti-inflammatory effects are typically rapid and are generally observed within a short time following the first dose.

How should Megasolone be stored and disposed of?

️ Information Unavailable: Official Storage and Disposal Profile

Official storage, handling, and disposal requirements for Megasolone have not been located within authoritative government drug regulatory documents (such as those published by the FDA, EMA, or NIH).

Regulatory agencies define a drug's profile by establishing mandatory conditions, including specific temperature ranges, protection from light or moisture, and detailed instructions for safe disposal, ensuring the medicine remains stable and effective until its expiration date. Without documented regulatory information for this specific product, its official storage and disposal protocol cannot be confirmed.

Always follow the specific instructions provided on the medication's official container labeling or patient information leaflet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.